Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) Products under Development by Stage of Development | 7 | 1 |
| MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) Products under Development by Therapy Area | 8 | 1 |
| MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) Products under Development by Indication | 9 | 1 |
| MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) Products under Development by Companies | 12 | 2 |
| MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) Products under Development by Universities/Institutes | 14 | 2 |
| MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) Therapeutics Assessment | 16 | 4 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 1 |
| Assessment by Route of Administration | 18 | 1 |
| Assessment by Molecule Type | 19 | 1 |
| MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) Companies Involved in Therapeutics Development | 20 | 4 |
| eFFECTOR Therapeutics, Inc. | 20 | 1 |
| Eli Lilly and Company | 21 | 1 |
| Merck &Co., Inc. | 22 | 1 |
| Selvita S.A. | 23 | 1 |
| MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) Drug Profiles | 24 | 12 |
| cercosporamide Drug Profile | 24 | 2 |
| eFT-508 Drug Profile | 26 | 2 |
| ETC-027 Drug Profile | 28 | 1 |
| ETC-17804452 Drug Profile | 29 | 1 |
| ETC-219 Drug Profile | 30 | 1 |
| SEL-201 Drug Profile | 31 | 1 |
| SLV-2436 Drug Profile | 32 | 1 |
| Small Molecules to Inhibit MAPKAP Kinase 2 for Inflammation Drug Profile | 33 | 1 |
| Small Molecules to Inhibit MNK1 and MNK2 for Oncology Drug Profile | 34 | 1 |
| Small Molecules to Inhibit Mnk2 for Acute Myeloid Leukemia Drug Profile | 35 | 1 |
| MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) Dormant Projects | 36 | 1 |
| MAP Kinase-Interacting Serine/Threonine-Protein Kinase 2 (Mitogen Activated Protein Kinase-Interacting Kinase 2 or MAP Kinase Signal-Integrating Kinase 2 or EC 2.7.11.1) Featured News &Press Releases | 37 | 2 |
| Mar 18, 2016: eFFECTOR Therapeutics to Present at the American Association for Cancer Research 2016 Annual Meeting | 37 | 1 |
| Jun 19, 2015: Peer-Reviewed Study in Cell Validates eFFECTOR Therapeutics' Novel Small-Molecule Approach to Cancer Treatment | 37 | 1 |
| Jan 06, 2015: eFFECTOR Therapeutics Initiates Dosing in Phase 1/2 Clinical Trial of eFT508 in Solid Tumors | 38 | 1 |
| Appendix | 39 | 2 |
| Methodology | 39 | 1 |
| Coverage | 39 | 1 |
| Secondary Research | 39 | 1 |
| Primary Research | 39 | 1 |
| Expert Panel Validation | 39 | 1 |
| Contact Us | 39 | 1 |
| Disclaimer | 40 | 1 |